New combo therapy offers hope for advanced lung cancer patients
NCT ID NCT07198217
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with advanced non-small cell lung cancer (stage IIIB/C-IV) who cannot tolerate standard chemoradiation. It tests a treatment plan of platinum-based chemotherapy, followed by a special type of radiation and the immunotherapy drug Tislelizumab. The goal is to see if this combination helps control the cancer for at least a year. About 20 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zibo Municipal Hospital
RECRUITINGZibo, Shandong, 250000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep lung cancer from returning after surgery?
- Could essential oils tame chemo nausea? a new trial puts aromatherapy to the test
- Shielding the ovaries: a drug may help young breast cancer patients preserve fertility during chemo
- Can surgery for stomach or esophageal cancer cloud the mind?
- Art therapy meets oncology: could mandala coloring boost cancer Patients' well-being?
- Could a chemo boost after radiation tame aggressive prostate cancer?